endpoint, a provider of Integrated Voice Response (IVR) and Integrated Web Response (IWR) systems, announced today its expansion into Europe with a European HQ office expected to open in early 2014.
endpoint
, a provider of Integrated Voice Response (IVR) and Integrated Web Response (IWR) systems, announced today its expansion into Europe with a European HQ office expected to open in early 2014. endpoint has doubled its revenue in the past two years and is forecasted to grow 40 percent in 2014.
endpoint is currently working on clinical trials in 40+ countries and the global expansion is seen as a natural progression for the company.
“It has long been our plan with our growing customer base in the Americas and Europe to add more resources in Europe.” said Jonathan Dole, co-founder and CEO, endpoint. “Not only is this a milestone for endpoint, but it also supports our growing European customer base.”
endpoint recently recruited Garrath Read as Director of Global Business Development, to support endpoint’s growth in Europe. Garrath comes from a global CRO background with over 15 years sales/healthcare experience.
“endpoint has been in the enviable position of meeting customers’ needs with a solution that can be implemented significantly faster than any of its competitors ,” said Garrath. “I’m very pleased to work for a company whose sole purpose is to create more efficient clinical trials with the patient being the winner.”
endpoint’s flagship product platform, PULSE, is fully configurable, allowing users to design and deploy clinical trial Integrated Response Technology (IRT) systems while saving 40 percent on the development time of clinical trials.
Endpoint will be exhibiting at the 12th annual Partnerships in Clinical Trials Congress in Vienna, Austria on the 20th-21st of November.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.